Immunotherapy with immune checkpoints inhibitors, specifically PD-1 and PD-L1, has demonstrated good responses in advanced NSCLC, ranging from 15 to 20%, with some patients exhibiting durable responses after discontinuing therapy [189,190,191,192,193,194]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.